Qilu, Lynk Score Phase III Wins In China Cancer, Atopic Dermatitis Trials
Qilu’s bifunctional drug of PD-1 and CTLA-4 antibodies hit in a cervical cancer trial, while Lynk’s JAK1 inhibitor triumphed in an atopic dermatitis trial.
Scrip - March 6, 2026

Execs On The Move: February 23–27, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - March 5, 2026

Don’t Use Anti-Choke Devices Unless Other Options Fail, FDA Says
The US FDA is warning that anti-choking devices can prove ineffective in emergencies and that methods established by the American Red Cross and the American Heart Association to remove blockages from choking victims should be tried first.
Medtech Insight - March 5, 2026

Cognito Raises $105M Series C Round To Fund Alzheimer’s Device, Adds Brain Health Partners
Cognito Therapeutics closed a new funding round to advance its Alzheimer’s headset toward FDA De Novo submission and planned 2027 launch while expanding its Brain Health Collaboratory to support adoption, reimbursement innovation, and pipeline growth.
Medtech Insight - March 5, 2026

PCPC Sues California AG Over Prop 65 Warnings for DEA in Cosmetics
For the second time in three years, the Personal Care Products Council is suing the California attorney general over the listing of a personal care ingredient under Proposition 65, citing a First Amendment violation.
HBW Insight - March 5, 2026

US Consumer Health People Moves: NACDS, USHR, Audien Hearing, Lindora, VALR Energy
VALR Energy names appoints chief revenue officer; CEO at Audien Hearing; Anderson retiring at NACDS; Lindora appoints president and chief medical officer; and USHR expands leadership.
HBW Insight - March 5, 2026

Bayer Consumer Health Predicts Continued Volatility Following Challenging Year
Bayer Consumer Health will lean on its "road to billions" strategy to achieve growth in 2026 against a volatile market backdrop.
HBW Insight - March 5, 2026

Geneva Forum: Whose Responsibility Is Self-Care? A View From Below
The second panel of this week's Geneva Self?Care Forum explored further the tension between self?care as a public?health tool and self?care as an out?of?pocket consumer market, raising sharp questions about where the industry sits.
HBW Insight - March 5, 2026

Geneva Forum: Lack Of Regulatory Framework For OTCs Holding Back Emerging Markets
The global consumer health industry sees emerging markets as an engine for growth in an otherwise stagnating market. But panelists at the Global Self-Care Forum in Geneva warned that regulatory gaps and lack of harmonization may stunt this potential in the short term.
HBW Insight - March 5, 2026

Sponsors Of OTC Switches, Other NDAs In US Provided Study Guide For Market Exclusivity Test
“New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers” draft guidance discusses statutory and regulatory criteria for three-year exclusivity eligibility and provides recommendations on content and format of requests.
HBW Insight - March 5, 2026

Three-Year Transition Allowed After 12-Digit NDCs Take Effect In Seven Years
FDA final rule effective date is March 7, 2033, when it will assign new 12-digit NDCs and convert all previously assigned 10-digit NDCs for OTC and Rx drugs to the 12-digit NDC format and start a three-year clock for compliance through March 6, 2036.
HBW Insight - March 5, 2026

Gedeon Richter’s Biotech Business Breaks Into Profit For The First Time
Hungarian pharma’s Q4 underlying profitability gain was boosted by strong CDMO activity, with steady-state profitability still targeted for 2027.
Generics Bulletin - March 5, 2026

Breaking Down The Pharmaceutical Regulatory (R)evolution With Medicines For Europe
Europe is facing one of the biggest pharmaceutical reforms in two decades. Medicines for Europe’s Beata Stepniewska and Adrian van den Hoven outlined how the regulatory trinity – EU pharmaceutical legislation, Critical Medicines Act, and Biotech Act – will reshape the industry.
Generics Bulletin - March 5, 2026

The Autonomous Lab: Part 1
In this two-part series, In Vivo examines who is building the autonomous lab, what architectural and business model choices they are making, and what the implications are for drug discovery organizations, external R&D partnerships and the workforce that will be asked to operate these systems.
In Vivo - March 5, 2026